What the FDA labels say about taking them together
Elbasvir/grazoprevir and ribavirin
Elbasvir/grazoprevir's FDA label of March 13, 2026 names ribavirin in its contraindications section; the ribavirin labels PlainMeds reads (2) do not name elbasvir/grazoprevir. The elbasvir/grazoprevir label: “Discontinue ZEPATIER in patients who develop evidence of hepatic decompensation/failure. Risk Associated with Ribavirin Combination Treatment:”
Check it at the source: the elbasvir/grazoprevir FDA label on DailyMed (effective March 13, 2026, Merck Sharp & Dohme LLC); the ribavirin FDA label on DailyMed (effective February 6, 2024, Aurobindo Pharma Limited).
What does the elbasvir/grazoprevir label say about ribavirin?
Elbasvir/grazoprevir label, contraindicationsIf ZEPATIER is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen.
Elbasvir/grazoprevir label, drug interactionsDrugs without Clinically Significant Interactions with ZEPATIER The interaction between the components of ZEPATIER (elbasvir or grazoprevir) or ZEPATIER and the following drugs were evaluated in clinical studies, and no dose adjustments are needed when ZEPATIER is used with the following drugs individually: acid reducing agents (proton pump inhibitors, H2 blockers, antacids), buprenorphine/naloxone, digoxin, dolutegravir, methadone, mycophenolate mofetil, oral contraceptive pills, phosphate binders, pitavastatin, pravastatin, prednisone, raltegravir, ribavirin, rilpivirine, tenofovir disoproxil fumarate, and sofosbuvir [see Clinical Pharmacology (12.3) ].
Elbasvir/grazoprevir label, warnings and precautionsDiscontinue ZEPATIER in patients who develop evidence of hepatic decompensation/failure. ( 5.3 ) Risk Associated with Ribavirin Combination Treatment:
Source: FDA drug label (ZEPATIER), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 164dc02a-9180-426a-b8b5-04ab39d2bbd4), via openFDA; the full label on DailyMed
What does the ribavirin label say about elbasvir/grazoprevir?
Ribavirin's label (effective February 6, 2024) and its 1 other brand-application label do not name elbasvir/grazoprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Ribavirin), Aurobindo Pharma Limited, effective February 6, 2024 (SPL set eee304d0-c2ea-44f4-97d9-92a414d31b6c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Elbasvir/grazoprevir | Ribavirin | |
|---|---|---|
| Labeled for | Hepatitis C | Hepatitis C |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.451 per tablet 200 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once